Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CLNNW 
Clene Inc (CLNNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: CLNNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -84.49% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 646.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 8762 | Beta 0.26 | 52 Weeks Range 0.02 - 0.08 | Updated Date 03/29/2025 |
52 Weeks Range 0.02 - 0.08 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -9510.99% |
Management Effectiveness
Return on Assets (TTM) -51.92% | Return on Equity (TTM) -1738.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5849354 |
Shares Outstanding - | Shares Floating 5849354 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Clene Inc
Company Overview
History and Background
Clene Inc., founded in 2012, is a clinical-stage biopharmaceutical company focused on developing nanotherapeutic solutions for neurodegenerative diseases. It has focused on clean-surfaced nanocrystals for disease modification.
Core Business Areas
- Neurodegenerative Disease Therapies: Clene's primary focus is developing therapies for neurodegenerative diseases like multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease. They utilize gold nanocrystals to potentially improve neuronal function.
Leadership and Structure
Rob Etherington serves as the CEO. The organizational structure includes departments focused on research and development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- CNM-Au8: CNM-Au8 is an oral gold nanocrystal suspension being developed for the treatment of neurodegenerative diseases. Market share data is not publicly available due to its investigational status. Competitors include companies developing therapies for MS, ALS, and Parkinson's such as Biogen (BIIB), Amylyx Pharmaceuticals (AMLX), and Teva Pharmaceutical Industries (TEVA).
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive, with significant investment in neurodegenerative disease research. There is a high unmet need for effective treatments.
Positioning
Clene is a smaller player focused on novel nanocrystal therapies. Its competitive advantage lies in its innovative approach to treating neurodegenerative diseases.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease therapies is substantial, estimated in the tens of billions of dollars annually. Clene is positioned to capture a portion of this market if its therapies are successful.
Upturn SWOT Analysis
Strengths
- Novel nanocrystal technology
- Focus on unmet medical needs
- Experienced management team
- Orally delivered drug
Weaknesses
- Limited financial resources
- Early stage of clinical development
- High regulatory risk
- Dependence on key products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion to new indications
- Breakthrough Therapy designation
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Amylyx Pharmaceuticals (AMLX)
- Teva Pharmaceutical Industries (TEVA)
Competitive Landscape
Clene faces stiff competition from established pharmaceutical companies with greater resources and approved therapies. Its advantage lies in its novel nanocrystal technology, but it must demonstrate clinical efficacy and safety to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by progress in clinical trials and securing funding.
Future Projections: Future growth is dependent on successful clinical trials and potential FDA approvals for CNM-Au8.
Recent Initiatives: Recent initiatives include advancing clinical trials for CNM-Au8 in MS, ALS, and Parkinson's disease.
Summary
Clene Inc. is a high-risk, high-reward clinical-stage biopharmaceutical company pioneering nanotherapeutic solutions for neurodegenerative diseases. Its innovative CNM-Au8 product has potential, but significant clinical and regulatory hurdles remain. Financial stability depends on continued funding and successful trial outcomes. Its ability to carve out market share will be largely determined by the success of these outcomes and the ability to secure partnerships.
Similar Companies
AMLX
Amylyx Pharmaceuticals Inc
AMLX
Amylyx Pharmaceuticals Inc
BIIB
Biogen Inc
BIIB
Biogen Inc
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- Clene Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and may be subject to change. Investing in clinical-stage biopharmaceutical companies involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clene Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 75 | Website https://clene.com |
Full time employees 75 | Website https://clene.com | ||
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.